H. pylori Testing and Eradication Confirmation: Breath, Stool and Follow-Up Tests

H. pylori testing asks whether a stomach infection is present; a post-treatment test asks whether it has cleared. Stool antigen and urea breath testing have clinical follow-up roles. Selected stool-test role; Actual breath-test service. Finishing antibiotics or feeling better does not by itself document eradication. Selected follow-up distinction. Confidence: high for these distinctions; moderate for attributed adult care frameworks. No independent comparative antibiotic, probiotic or commercial-kit verdict is established.

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What H. pylori infection and eradication testing mean

Helicobacter pylori is a bacterium that lives in the mucus coating the stomach. NCI describes how it survives the local acidic environment. Selected dated anatomy. It is a specific infection, rather than a name for every form of indigestion, reflux or an altered microbiome.

The NHS identifies H. pylori among causes of gastritis and peptic ulcers, while also recognizing other causes. Current cause context; Selected ulcer context. Ask which clinical question led to testing and whether the clinician also needs to investigate a different explanation for your symptoms.

Keep three records distinct: the original test, prescribed treatment and the later result. A prescription proves that treatment was planned, while a laboratory report answers its own stated question. Ask the service to identify what is known, what is pending and who will explain the result.

Breath, stool antigen and biopsy tests: different ways to investigate

Leeds’ laboratory service uses stool antigen detection for initial diagnosis and assessment after treatment. Its description also warns that recent antimicrobials, proton pump inhibitors and bismuth can suppress the infection and produce a false-negative result. Selected test role and interference. No performance percentage or universal preparation calendar is adopted here.

Cambridge’s dyspepsia service offers urea breath testing after eradication therapy. Actual local follow-up service. Ask which test the clinician ordered; a breath-test name alone is not enough to identify its purpose. Follow the instructions belonging to that particular service and test.

Gastroscopy examines the food pipe, stomach and upper intestine and may take tissue samples. Current selected examination role. If endoscopy is proposed, ask what additional question it addresses and how any pending tissue result will be followed up. A non-invasive infection test and an examination of stomach tissue are different investigations.

Treatment selection and confirmation after the course

The NHS describes antibiotics for H. pylori-associated ulcers and acid-reducing treatment where indicated. Selected treatment roles. Omeprazole, for example, has a role alongside antibiotics rather than proving eradication by itself. Selected medicine role. Ask for the actual prescribed combination and an explanation of each component.

ACG’s adult framework considers previous antibiotic exposure, prior eradication attempts and penicillin allergy; it cautions against certain antibiotic regimens without demonstrated susceptibility. Selected resistance framework. This is an attributed North American clinical framework, not an independent product ranking or a universal prescription for every country.

The society’s highlights include a test-of-cure plan using appropriately arranged breath, stool or selected biopsy-based testing. Selected follow-up options. Agree how it will be requested and where the result goes before assuming that the course closes the clinical episode. This article supplies no drug dose, treatment duration or self-directed repeat course.

Food, probiotics and claims to remove H. pylori

For ulcer symptoms, the NHS distinguishes symptom support such as smoking cessation and avoiding personal food triggers from infection treatment. Selected supportive context. A change in burning, bloating or appetite is useful to report, but is not a microbiological result.

NCCIH describes supplement interactions and possible harm. Selected dated safety context. No probiotic strain, herbal product, food, “detox” or commercial microbiome programme is independently established here to replace the prescribed pathway or confirm eradication.

Ask what a product claim actually measured: a laboratory mechanism, symptom change, treatment tolerance or a properly conducted infection test. Those outcomes are not interchangeable. Tell the clinician or pharmacist about products already used and any nutrition or swallowing difficulty that may complicate the prescribed plan.

What a negative, positive or antibody result can establish

ACG excludes persistent antibody results from confirmation of eradication. Selected antibody limitation. Ask whether a reported blood result measures antibodies rather than active infection. Do not interpret an old antibody report as a new test of cure.

For any result, request its date, test type and the context in which it was collected. Tell the service what medicines were taken recently and whether the intended preparation was possible. Ask whether the actual result answers the question or requires further interpretation; do not arrange an improvised medicine pause yourself.

A negative infection test also does not name the cause of every continuing symptom. Ask what assessment remains necessary and what the next step is if the original question is unresolved. This guide gives no home rule for deciding that a test is invalid or that another antibiotic course is needed.

Bleeding and other warning signs while awaiting tests

Current NHS gastritis guidance treats vomiting blood or coffee-ground material, black sticky stool, or severe sudden abdominal/chest pain as emergencies. It calls for prompt assessment of swallowing difficulty, repeated vomiting or unexplained weight loss. Current urgent and emergency categories. Use the equivalent local emergency or urgent service outside the UK.

Do not wait for a routine breath-test appointment or planned result review to raise an acute concern. Give the assessing team the medicine list, actual recent symptoms and any previous ulcer or endoscopy report. A possible infection is only part of that assessment.

If gastroscopy forms part of the investigation, obtain its own aftercare and urgent-contact instructions. The current NHS procedure source identifies worsening severe pain, vomiting blood or shortness of breath after the procedure as emergency reasons. Selected current aftercare warnings. A pending tissue result does not postpone assessment of a possible complication.

Antibiotic and acid-suppression risks and interactions

The NHS antibiotic safety source lists diarrhoea and nausea among possible effects and identifies breathing difficulty, throat/chest tightness or facial/tongue swelling as potential severe allergic reactions needing emergency care. Selected safety warnings. No reassurance that a reaction is rare or harmless is supplied here.

The omeprazole source identifies possible interactions with medicines including clopidogrel, warfarin, digoxin and St John’s wort, and advises checking the complete medicine list. Selected interaction context. This is selected safety information rather than a complete interaction checker for every eradication combination.

Ask the pharmacist or prescriber to review allergies, prescriptions, non-prescription products and exact formulations together. If an adverse effect interferes with treatment, seek their advice rather than borrowing a substitute or changing the combination. The appropriate response depends on the actual reaction and medicine.

Who needs an individualized testing and treatment plan

Discuss pregnancy, breastfeeding, childhood, prior drug reactions, major medical conditions and an inability to tolerate or swallow the prescribed medicines. This adult educational framework provides no blanket eligibility, pregnancy clearance or pediatric regimen.

National gastroscopy advice asks patients to disclose pregnancy and medicines and follow their own hospital’s instructions. Selected assessment and preparation roles. For non-invasive testing, ask the laboratory how its own sampling and preparation instructions apply to your circumstances.

Tell the clinician about previous H. pylori treatment, persistent symptoms, prior ulcer findings and any stomach-cancer or inherited-risk assessment already in progress. Ask which service owns each decision. A routine test request should not be used to cancel a separate investigation or existing specialist follow-up without discussion.

Practical follow-up: medicine history, test preparation and results

Keep the names of prescribed medicines, treatment dates, difficulties completing the course and the original result. Ask for written instructions identifying the follow-up test, any clinician-approved preparation changes, the responsible service and how to obtain the result.

The omeprazole information warns that it can affect some investigations and directs patients to the actual testing service about any proposed pause. Selected test-planning advice. This guide supplies no stopping interval, alternative acid medicine, fasting rule or antibiotic/bismuth washout calendar.

If instructions differ between a laboratory leaflet and prescriber, ask them to reconcile the plan. Report a missed sample or incomplete preparation. At the result discussion, ask whether infection status is established, whether symptoms still need investigation and who coordinates a possible further treatment decision.

Infection clearance, symptom relief and independent evidence limits

An infection result, ulcer healing, improvement in indigestion and a long-term cancer outcome are separate measures. This guide does not turn a test result into a promise about every future symptom or risk.

NCI describes chronic stomach inflammation and associations with gastric adenocarcinoma and gastric MALT lymphoma. Selected dated disease context. That background is not a personal prediction, a cancer diagnosis or an independently audited eradication benefit estimate.

Animal or cell findings cannot establish that a product clears human infection. This article does not adopt corporate trial outcomes, including null outcomes, through a guideline or public summary. Relevant original trials, controls, patient outcomes and financial chains require separate review before an independent efficacy conclusion.

Funding and source roles

National NHS advice and the Leeds/Cambridge services have different financial routes, recorded separately below. Public care or research income does not establish the payments behind an individual test, contributor or underlying study.

The full ACG paper discloses relevant drug/diagnostic interests alongside its methodology. The one-page highlights remain an abbreviated framework from the same author group. Their recommendations provide clinical context; neither format clears a sponsored trial for an independent verdict.

NCI’s older fact sheet is used for selected anatomy and disease context, excluding its historical testing menu, prevalence and treatment-outcome claims. Its budget and gift authority are separate institutional records. Complete contributor, backer and original-study allocations remain unresolved.

Frequently asked questions

Does feeling better prove H. pylori is gone? No; symptoms and a properly arranged post-treatment result answer different questions. Ask for the agreed follow-up result.

How should I interpret an antibody blood result? Ask what it measured and which follow-up assessment actually answers your question; see the result distinction above.

Should I stop my acid medicine before testing? Ask the testing service and prescriber for the actual written plan. No personal stopping schedule is provided.

Is a negative result a complete explanation of stomach symptoms? Ask what it established and what other assessment remains necessary; an infection test does not diagnose every cause.

Can I repeat leftover antibiotics or substitute a supplement? No independent substitution is established here. Further treatment requires review of the actual result and medicine history.

What should I keep? The original report, prescribed course details, test-specific instructions, follow-up result and responsible contact.

Sources and funding notes

Actual August 2026 gastritis, August 2025 ulcer, September 2025 omeprazole, dated November 2022 antibiotic safety and August 2026 gastroscopy originals opened; selected clinical/safety roles only. Antibiotic-page scheduled review passed; dated class-specific wording and rarity reassurance excluded. Leeds actual test body and own 220-page 2025–2026 accounts notes3–4 and industry-research passages read; clinical test-page revision date unclosed. CUH actual dyspepsia/breath-service body read; printing timestamp not clinical review, named contributor financial chains unclosed; own 197-page current accounts separately checked. Full 24-page September 2024 ACG primary paper retrieved through a public replica, DOI10.14309/ajg.0000000000002968; selected passages and declarations read. One-page own society highlights independently opened. Known author interests are Tier3/C; original-study allocations remain unclosed. No corporate trial benefit or null outcome imported into an independent verdict. NCI April 2023 selected anatomy/disease context plus own May 2026 budget, April 2018 gift authority and office-contact originals checked; old policy and trial outcomes excluded. National NHS accounts/policy and NCCIH historical budget/gift authority separately traced. Complete current donor, contributor and study-payment chains remain unclosed. No personal dose, test pause, fasting, treatment duration, diagnostic cutoff, response deadline, test-performance rate or recovery guarantee supplied.

1. National NHS gastritis, August 5, 2026 — Selected current cause and urgent-warning context; symptom wait and home treatment rules excluded
2. National NHS stomach/duodenal ulcer, August 12, 2025 — Selected infection/other-cause distinction and clinical treatment/support roles; no outcome rate or course duration
3. Leeds Teaching Hospitals original H. pylori stool-test service; revision date unclosed — Selected stool-test and medicine-interference roles; comparative performance and local preparation calendar excluded
4. Cambridge University Hospitals dyspepsia/urea-breath-test service; clinical revision date unclosed — Actual local urea-breath service role only; clinical revision and contributor interests unclosed
5. Original ACG H. pylori guideline 2024, full 24-page mirrored primary paper — Selected adult resistance/serology/follow-up distinctions plus actual primary author declarations; drug/probiotic benefit and prescribing menu excluded
6. ACG own 2024 guideline highlights, full 1-page ; posted 2025 — Selected test-of-cure options only; personal doses, timing, eligibility thresholds and brand ranking excluded
7. National NHS omeprazole, September 17, 2025; selected safety only — Selected medicine, interaction and test-service roles; no dose, medicine pause or blanket pregnancy safety
8. National NHS antibiotic side effects, November 11, 2022; review due passed — Selected adverse-effect/emergency context; rarity reassurance and class-specific personal stopping protocols excluded
9. National NHS gastroscopy information, August 13, 2026 — Selected current examination/preparation/urgent-warning roles; fasting, recovery, response calendars and painless reassurance excluded
10. NCI H. pylori/cancer education, April 12, 2023; selected anatomy only — Selected dated stomach anatomy/inflammation/cancer context; all prevalence, historical testing policies and treatment outcomes excluded
11. NCCIH supplement safety, January 2019; selected safety context only — Selected dated supplement safety, not evidence of H. pylori efficacy
12. Leeds Teaching Hospitals own 2025–2026 audited accounts, full 220-page — Own current provider income notes and industry-research route, not exact test funding
13. Cambridge University Hospitals own 2025–2026 audited accounts — Separate own current provider finance, not national NHS-only attribution
14. ACG Institute original G.U.T. Fund industry/donation route and contact — Separate society industry/gift model and North Bethesda contact; full ledger unclosed
15. NCI own budget explanation, May 14, 2026; enacted/requested funding separate — Actual public institutional funding explanation; future requests separate
16. NCI own gift agreement authority, April 2018, full 4-page — Separate dated gift authority, not named receipts
17. NCI own communications-office contact/location — Actual own institutional jurisdiction
18. NHS England own 2025–2026 audited accounts — Separate current national audited funding
19. National NHS website content and funding policy, 2022 — Separate dated national website policy, not provider finances
20. NCCIH actual appropriation history, through FY2024 — Separate historical appropriation account
21. NCCIH separate conditional/unconditional Gift Fund authority — Separate permitted gift route; current receipts and exact page allocation unclosed

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.